Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Janux Therapeutics, Inc. (JANX : NSDQ)

• Company Description    Janux Therapeutics Inc. is a biopharmaceutical company. It involved in developing novel T cell engager immunotherapies. Janux Therapeutics Inc. is based in LA JOLLA, Calif. Number of Employees: 81

• Price / Volume Information    Yesterday's Closing Price: $13.61 Daily Weekly Monthly 20 Day Moving Average: 1,084,148 shares Shares Outstanding: 60.83 (millions) Market Capitalization: $827.92 (millions) Beta: 2.88 52 Week High: $35.34 52 Week Low: $12.12 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -0.73% 0.14% 12 Week -17.57% -17.67% Year To Date -1.38% -1.86%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 10955 Vista Sorrento Parkway Suite 200 - San Diego,CA 92130 USA ph: 858-751-4493 fax: - investors@januxrx.com http://www.januxrx.com

• General Corporate Information    Officers David Campbell - President and Chief Executive Officer and Director Ron Barrett - Chairperson of the Board of Directors Janeen Doyle - Chief Corporate and Business Development Officer Vickie Capps - Director Eric Dobmeier - Director Peer Information Janux Therapeutics, Inc. (CORR.) Janux Therapeutics, Inc. (RSPI) Janux Therapeutics, Inc. (CGXP) Janux Therapeutics, Inc. (BGEN) Janux Therapeutics, Inc. (GTBP) Janux Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 47103J105 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 12/01/25 Next Expected EPS Date: 05/14/26 Share - Related Items Shares Outstanding: 60.83 Most Recent Split Date: (:1) Beta: 2.88 Market Capitalization: $827.92 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.66 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.04 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 10.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 05/14/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.86 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -41.67% vs. Previous Quarter: -30.77% Sales Growth vs. Year Ago Period: 2,177.90% vs. Previous Quarter: -% ROE 12/31/25 - -12.61 09/30/25 - -10.18 06/30/25 - -11.48 ROA 12/31/25 - -12.08 09/30/25 - -9.78 06/30/25 - -11.01 Current Ratio 12/31/25 - 39.04 09/30/25 - 35.86 06/30/25 - 47.03 Quick Ratio 12/31/25 - 39.04 09/30/25 - 35.86 06/30/25 - 47.03 Operating Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Net Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Pre-Tax Margin 12/31/25 - -1,136.25 09/30/25 - -1,018.95 06/30/25 - -24,064.01 Book Value 12/31/25 - 15.91 09/30/25 - 16.25 06/30/25 - 16.74 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - 0.00 09/30/25 - 0.00 06/30/25 - 0.00 Debt-to-Capital 12/31/25 - 0.00 09/30/25 - 0.00 06/30/25 - 0.00

Powered by Zacks Investment Research ©